Aprinocarsen
Alternative Names: Affinitac; Affinitak; Aprenocarsen sodium; CGP 64128A; ISIS 3521; LY 900003Latest Information Update: 24 Oct 2021
At a glance
- Originator Isis Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer; Breast cancer; Colorectal cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 04 Mar 2005 Discontinued - Phase-II for Brain cancer in Canada (IV-infusion)
- 04 Mar 2005 Discontinued - Phase-II for Brain cancer in Europe (IV-infusion)
- 04 Mar 2005 Discontinued - Phase-II for Brain cancer in USA (IV-infusion)